Business Interests

Business Interests 2017-12-05T15:51:28+00:00

Autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered T-cell immunotherapy products to combat cancer. Utilising its advanced cell programming and manufacturing technologies, Autolus has a pipeline of products in development for the treatment of both haematological malignancies and solid tumours.


Amplyx Pharmaceuticals is developing novel, broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. Amplyx has raised $118.5 million in venture capital and secured more than $10 million in grants from the National Institutes of Health to support its drug discovery and development efforts.


Artios is a leading independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programmes, including through a unique partnership with Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide.

Atox Bio

Atox Bio is a late stage clinical biotechnology company with operations in the US and Israel that develops novel immune modulators for critically ill patients with severe infections including necrotising soft tissue infections (NSTI) and acute kidney injury (AKI). Atox Bio’s lead therapeutic candidate, Reltecimod, is a novel peptide that modulates the body’s immune response, lowering the risk of potential morbidities and mortality. Reltecimod received Orphan Drug status from the FDA and EMA as well as Fast Track designation. Atox Bio is conducting a Phase 3 clinical study of Reltecimod for patients with NSTIs, and will start a Phase 2 clinical study for AKIs in 2018.


Harpoon is a preclinical stage biotechnology company founded by Patrick Baeuerle, Ph.D. and MPM Capital to develop multiple T-cell recruiting platforms leading to therapies for cancer patients and other immunologic disorders. Harpoon created its proprietary TriTAC™ biologics platform to harness T cells to kill tumor and other cell types by recruiting T cells and other immune cells. This approach has been optimized to penetrate tissues and extend serum exposure and has the potential to address a broad range of cancers and immunologic diseases. HPN424, a prostate-specific membrane antigen (PSMA)-targeting TriTAC™ biologic, is in development for the treatment of prostate cancer.

Iterum Therapeutics

Iterum Therapeutics Limited is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing its first compound, sulopenem, a novel penem anti-infective compound with oral and IV formulations in an IV only class of antibiotics that has demonstrated potent in-vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received QIDP designations for its oral and IV formulations for the treatment of uUTI, cUTI and cIAI.


LogicBio is a preclinical-stage gene-therapy company with a mission to develop cures for life-threatening diseases. Founded by pioneers in gene therapy from leading academic institutions including Stanford University, Tel Aviv University, and Children’s Medical Research Institute in Australia, LogicBio’s core platform includes synthetic gene-therapy vectors derived from naturally occurring human adeno-associated viruses and the GeneRide technology.

LogicBio designed its approach to harness the natural power of homologous recombination enabling precise, site-specific transfer of the genetic material without the use of promoters or nucleases. The goal: repairing the faulty genetic sequence causing the disorder to deliver a cure. LogicBio is advancing programs targeting rare, life-threatening paediatric genetic diseases of the liver, where there are few, if any, treatment options.


PreciThera, Inc. is a biotechnology company committed to the development of therapies for rare bone diseases using the combined application of computational technology and a deep understanding of disease pathology. The company focuses on heterogeneous genetic disorders that primarily manifest in bone dysfunction. Understanding of novel biology will allow PreciThera’s targeted strategies to meaningfully impact both the skeletal symptoms as well as the extraskeletal issues found in these patients.

Mitoconix Bio Ltd

Mitoconix Bio Ltd is pioneering a novel strategy to improving mitochondrial health as a disease-modifying therapeutic for neurodegenerative diseases. Mitoconix Bio’s lead drug is a first-in-class inhibitor of pathological mitochondrial fragmentation and dysfunction with demonstrated in vivo efficacy in animal models of Huntington’s (HD) and Parkinson’s diseases (PD) and beneficial activity in patient-derived cells of HD, sporadic and genetic PD, and sporadic and genetic Alzheimer’s disease (AD).


Depixus is a young and dynamic biotechnology company based in Paris. Its goal is to commercialise a highly innovative technology platform for the fast, accurate, and inexpensive extraction of genetic and epigenetic information from single molecules of DNA and RNA. Originally developed in the Physics Department of École Normale Supérieure (ENS) in Paris, the potential of this exciting technology has been recognised through the award of numerous grants and innovation prizes at both national and international levels.

Verona Pharma plc

Verona Pharma plc is a UK-based clinical stage biotech company focused on the development of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. Verona Pharma’s lead drug, RPL554, is a first-in-class drug currently in Phase 2 trials as a nebulised treatment for COPD patients with moderate to severe disease and possibly as a treatment of acute exacerbations of COPD in the hospital setting.

The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both bronchodilator and anti-inflammatory effects, which are essential to the improvement of patients with COPD and asthma. Verona Pharma is also building a broader portfolio of RPL554-containing products for COPD and asthma maintenance therapy, and is exploring the potential of the drug in different diseases, such as cystic fibrosis.


OptiKira is developing novel therapeutics to prevent cell death. Founded in 2015, the company’s technology is based on discoveries developed and exclusively licensed from the University of California, San Francisco. Extensive research by the founders on the unfolded protein response has helped define the biological pathway leading to progressive cell death which characterises diseases such as retinitis pigmentosa, diabetes, and amyotrophic lateral sclerosis.


BioMotiv is the mission-driven research accelerator associated with The Harrington Project for Discovery & Development, a $300 million initiative for advancing medicine centred at University Hospitals in Cleveland. The focus is to accelerate breakthrough discoveries from research institutions into therapeutics for patients through an innovative model that efficiently aligns capital and collaborations. The company leverages an experienced team and advisory board to select, fund, and actively manage and advance a portfolio of programs.